Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Clinical Trials
521
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (417 trials with phase data)• Click on a phase to view related trials
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
- Locations
- 🇺🇸
Trialmed formerly PPD, Austin Clinic, Austin, Texas, United States
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 255
- Registration Number
- NCT06953583
- Locations
- 🇺🇸
UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California, United States
🇺🇸Norman Fixel Institute for Neurological Diseases UF Health, Gainesville, Florida, United States
🇺🇸USF Health Morsani College of Medicine Department of Neurology, Tampa, Florida, United States
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 454
- Registration Number
- NCT06935357
- Locations
- 🇺🇸
Kidney & Hypertension Center - Apple Valley, Apple Valley, California, United States
🇺🇸North America Research Institute-San Dimas, San Dimas, California, United States
🇺🇸American Clinical Trials LLC, Acworth, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 100
- Next
News
IXICO Secures Full Data Rights to Landmark Bio-Hermes-002 Alzheimer's Study Through Strategic GAP Partnership
IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.
FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring
The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.
Harrow Secures Exclusive US Rights to Samsung Bioepis Ophthalmology Biosimilars Portfolio
Harrow has entered into a partnership with Samsung Bioepis to gain exclusive US commercial rights to two FDA-approved ophthalmology biosimilars, BYOOVIZ and OPUVIZ, following Biogen's termination of its commercialization agreement.
Vor Bio Appoints Telitacicept Development Expert Dr. Qing Zuraw as Chief Development Officer
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
Brenig Therapeutics Appoints New Leadership and Expands Parkinson's Disease Pipeline with NLRP3 Inhibitor Acquisition
Brenig Therapeutics appointed David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer to advance its neurodegenerative disease pipeline.
Biogen and Acumen Advance Alzheimer's Research with Long-Term Data and Novel Targeting Approaches at AAIC 2025
Biogen presents 48-month data from LEQEMBI's Clarity AD open-label extension study and introduces subcutaneous formulation for maintenance dosing at AAIC 2025.
Zorevunersen Shows Promising Cognitive and Behavioral Improvements in Dravet Syndrome Phase 3 Trial Analysis
Biogen and Stoke Therapeutics presented new data showing zorevunersen improved cognition and behavior at Week 68 in a Phase 3 dosing regimen analysis for Dravet syndrome patients.
Alzheimer's Drug Market Sees 780% Investment Surge Following Leqembi and Kisunla Approvals
Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.
Q32 Bio Names Adrien Sipos as Interim CMO to Lead Alopecia Areata Drug Development
Q32 Bio appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to oversee the ongoing SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata treatment.